CNMD on NYSE

CONMED Corporation

American medical equipment company

The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

Compare with LivaNova PLC, Integer or TransMedics Group, Inc., or pick any stock.

  • TickerCNMD on NYSE1
  • IndustryElectromedical & Electrotherapeutic Apparatus1
  • HeadquartersLargo1
  • Websitewww.conmed.com
  • Incorporated inDE4
  • Business address11311 Concept Boulevard, Largo, Fl 337734
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices internationally, and a vast global footprint.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

54.6%Gross margin6
7.5%Operating margin6
3.4%Net margin6
5.2%Revenue growth, 20256
4.6%Return on equity6
$150.9MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

General Surgery brought in 58% of the revenue CONMED Corporation broke down this way in fiscal 2025.

  1. General Surgery$800.1M658%up 5% from 2024
  2. Orthopedic Surgery$574.6M642%up 6% from 2024
Products and services by year
Products and services202320242025
General Surgery$711.6M$763.0M$800.1M
Orthopedic Surgery$533.2M$544.0M$574.6M

Regions

United States brought in 56% of the revenue CONMED Corporation broke down this way in fiscal 2025.

  1. United States$774.6M656%up 4% from 2024
  2. EMEA$264.7M619%up 9% from 2024
  3. Asia Pacific$208.7M615%up 7% from 2024
  4. Americas (excluding the United States)$126.8M69%up 5% from 2024
Regions by year
Regions202320242025
United States$700.2M$748.2M$774.6M
EMEA$226.3M$243.1M$264.7M
Asia Pacific$197.4M$194.7M$208.7M
Americas (excluding the United States)$120.9M$121.0M$126.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue45¢$624.2M
  • Research and development4¢$55.9M
  • Selling, general and admin43¢$592.0M
  • Interest2¢$31.1M
  • Income tax2¢$24.1M
  • Profit3¢$47.1M

Out of $1.4B in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending12¢$19.8M
  • Dividends paid14¢$24.7M
  • Kept or used elsewhere74¢$126.1M

Out of $170.7M of cash from operations.6

Financial statements

Revenue789106$1.4B in 2025+44% since 2019
0$500.0M$1.0B$1.5B2019: $955.1M$955.1M20192020: $862.5M$862.5M2020−10%2021: $1.0B$1.0B2021+17%2022: $1.0B$1.0B2022+3%2023: $1.2B$1.2B2023+19%2024: $1.3B$1.3B2024+5%2025: $1.4B$1.4B2025+5%
Gross profit789106$750.5M in 2025+43% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $524.7M$524.7M20192020: $460.3M$460.3M2020−12%2021: $568.0M$568.0M2021+23%2022: $571.2M$571.2M2022+1%2023: $676.2M$676.2M2023+18%2024: $733.0M$733.0M2024+8%2025: $750.5M$750.5M2025+2%
Operating income789106$102.6M in 2025+30% since 2019
0$100.0M$200.0M$300.0M2019: $79.1M$79.1M20192020: $46.0M$46.0M2020−42%2021: $109.7M$109.7M2021+138%2022: $70.1M$70.1M2022−36%2023: $120.6M$120.6M2023+72%2024: $200.3M$200.3M2024+66%2025: $102.6M$102.6M2025−49%
Net income789106$47.1M in 2025+64% since 2019
-$100.0M0$100.0M$200.0M2019: $28.6M$28.6M20192020: $9.5M$9.5M2020−67%2021: $62.5M$62.5M2021+557%2022: -$80.6M-$80.6M20222023: $64.5M$64.5M20232024: $132.4M$132.4M2024+105%2025: $47.1M$47.1M2025−64%

Every line of the income statement in the latest annual report, as filed.6

Period ending2025-12-312024-12-312023-12-31
Net sales$1.4B$1.3B$1.2B
Cost of sales$624.2M$574.0M$568.5M
Gross profit$750.5M$733.0M$676.2M
Selling and administrative expense$592.0M$478.3M$503.0M
Research and development expense$55.9M$54.4M$52.6M
Operating expenses$647.9M$532.7M$555.6M
Income from operations$102.6M$200.3M$120.6M
Interest expense$31.1M$37.3M$39.8M
Other expense$418.0K$0$0
Income before income taxes$71.1M$163.0M$80.8M
Provision for income taxes$24.1M$30.6M$16.4M
Net income$47.1M$132.4M$64.5M
Basic (in dollars per share)$1.52$4.29$2.10
Diluted (in dollars per share)$1.51$4.25$2.04
Cash flow hedging-$6.9M$5.5M-$3.1M
Pension liability$3.4M$2.5M$6.6M
Foreign currency translation adjustments$15.2M-$14.8M$5.1M
Other comprehensive income (loss), before income tax$11.7M-$6.7M$8.5M
Provision (benefit) for income taxes related to items in other comprehensive income (loss)-$834.0K$1.9M$832.0K
Other comprehensive income (loss), net of income tax$12.6M-$8.7M$7.7M
Comprehensive income$59.6M$123.7M$72.1M

Compare CONMED Corporation with another company

The story

In 1970, Eugene Corasanti (1930–2015) purchased a small medical supplied distributor in Utica, New York. He originally named the company Concor Enterprises, but later renamed it to Consolidated Medical Equipment, Inc. Its first product was a disposable ECG electrode. Growing through acquisitions, Corasanti served as CEO until 2006 when Curt Hartman gained the President, CEO, and Chairman of the Board position in 2014. Pat Beyer took over as President and CEO on January 1, 2025.

Today, CONMED remains focused on assisting healthcare providers enhance patient outcomes.

From Wikipedia’s article on CONMED Corporation, shared under CC BY-SA 4.0.5

Acquisitions

1989: Aspen Labs from Bristol-Myers Squibb

1995: New Dimensions in Medicine Inc. and the Birtcher Corporation, manufacturer of the Hyfrecator

1997: Linvatec Corp, from Bristol-Myers Squibb

2002: ValMed and NorTrex Medical

Read the full text

2003: Core Dynamics and Bionx Implants

2004: Endoscopic unit of C R Bard Inc

2012: Viking Systems

2016: SurgiQuest

2017: ExoShape ACL product line from MedShape

2019: Buffalo Filter

2022: In2Bones and Biorez

From Wikipedia’s article on CONMED Corporation, shared under CC BY-SA 4.0.5

Recent filings

  1. Sep 10, 20264 PRIMARY DOCUMENT
  2. Jul 29, 20268-K
  3. Jul 29, 202610-Q
  4. Jul 17, 20263 PRIMARY DOCUMENT
  5. Jul 17, 20264 PRIMARY DOCUMENT
  6. Jul 2, 20263 PRIMARY DOCUMENT
  7. Jul 2, 20263 PRIMARY DOCUMENT
  8. Jul 2, 20264 PRIMARY DOCUMENT
  9. Jul 2, 20264 PRIMARY DOCUMENT
  10. Jun 17, 20268-K CURRENT REPORT
  11. Jun 16, 202611-K
  12. Jun 4, 20268-K
  13. Jun 3, 20263 PRIMARY DOCUMENT
  14. Jun 3, 20263/A PRIMARY DOCUMENT
  15. Jun 3, 20264 PRIMARY DOCUMENT

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14